A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Public ClinicalTrials.gov record NCT06593522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Anvumetostat in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).
Study identification
- NCT ID
- NCT06593522
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 25, 2024
- Primary completion
- Oct 30, 2026
- Completion
- Nov 29, 2026
- Last update posted
- May 27, 2026
2024 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| City of Hope Orange County Lennar Foundation Cancer Center | Duarte | California | 91010 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Eastern Connecticut Hematology and Oncology Associates | Norwich | Connecticut | 06360 | — |
| Hartford HealthCare Cancer Institute - Manchester | Plainville | Connecticut | 06062 | — |
| Medstar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Our Lady of the Lake Cancer Institute | Baton Rouge | Louisiana | 70808 | — |
| Trinity Health Saint Joseph Mercy Ann Arbor | Ann Arbor | Michigan | 48106 | — |
| Cancer and Hematology Centers of Western Michigan | Grand Rapids | Michigan | 49503 | — |
| Sarah Cannon Research Institute Oncology Partners | Nashville | Tennessee | 37203 | — |
| United States Oncology Regulatory Affairs Corporate Office | Nashville | Tennessee | 37203 | — |
| Texas Oncology Central/South Texas | Austin | Texas | 78745 | — |
| Sarah Cannon Research Institute | Dallas | Texas | 75230 | — |
| Texas Oncology - Dallas Fort Worth | Dallas | Texas | 75246 | — |
| US Oncology Research Investigational Products Center | Irving | Texas | 75063 | — |
| Texas Oncology Northeast Texas | Tyler | Texas | 75702 | — |
| Virginia Cancer Specialists PC | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06593522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 27, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06593522 live on ClinicalTrials.gov.